Anti-ES8L2/ EPS8L2/ DFNB106 monoclonal antibody

Anti-ES8L2/ EPS8L2/ DFNB106 antibody for FACS & in-vivo assay

Target products collectionGo to EPS8L2/EPS8L2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2111-Ab-1/ GM-Tg-hg-MP2111-Ab-2Anti-Human EPS8L2 monoclonal antibodyHuman
GM-Tg-rg-MP2111-Ab-1/ GM-Tg-rg-MP2111-Ab-2Anti-Rat EPS8L2 monoclonal antibodyRat
GM-Tg-mg-MP2111-Ab-1/ GM-Tg-mg-MP2111-Ab-2Anti-Mouse EPS8L2 monoclonal antibodyMouse
GM-Tg-cynog-MP2111-Ab-1/ GM-Tg-cynog-MP2111-Ab-2Anti-Cynomolgus/ Rhesus macaque EPS8L2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2111-Ab-1/ GM-Tg-felg-MP2111-Ab-2Anti-Feline EPS8L2 monoclonal antibodyFeline
GM-Tg-cang-MP2111-Ab-1/ GM-Tg-cang-MP2111-Ab-2Anti-Canine EPS8L2 monoclonal antibodyCanine
GM-Tg-bovg-MP2111-Ab-1/ GM-Tg-bovg-MP2111-Ab-2Anti-Bovine EPS8L2 monoclonal antibodyBovine
GM-Tg-equg-MP2111-Ab-1/ GM-Tg-equg-MP2111-Ab-2Anti-Equine EPS8L2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2111-Ab-1/ GM-Tg-hg-MP2111-Ab-2; GM-Tg-rg-MP2111-Ab-1/ GM-Tg-rg-MP2111-Ab-2;
GM-Tg-mg-MP2111-Ab-1/ GM-Tg-mg-MP2111-Ab-2; GM-Tg-cynog-MP2111-Ab-1/ GM-Tg-cynog-MP2111-Ab-2;
GM-Tg-felg-MP2111-Ab-1/ GM-Tg-felg-MP2111-Ab-2; GM-Tg-cang-MP2111-Ab-1/ GM-Tg-cang-MP2111-Ab-2;
GM-Tg-bovg-MP2111-Ab-1/ GM-Tg-bovg-MP2111-Ab-2; GM-Tg-equg-MP2111-Ab-1/ GM-Tg-equg-MP2111-Ab-2
Products NameAnti-EPS8L2 monoclonal antibody
Formatmab
Target NameEPS8L2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-EPS8L2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ES8L2/ EPS8L2/ DFNB106 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2111
    Target NameEPS8L2
    Gene ID64787,98845,361674,720824,100856027,101083295,614857,100055949
    Gene Symbol and SynonymsDFNB106,EPS8L2,EPS8R2
    Uniprot AccessionQ9H6S3
    Uniprot Entry NameES8L2_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseMalignant neoplasm of bladder
    Gene EnsemblENSG00000177106
    Target ClassificationN/A

    The target: EPS8L2, gene name: EPS8L2, also named as DFNB106, EPS8R2. This gene encodes a member of the EPS8 gene family. The encoded protein, like other members of the family, is thought to link growth factor stimulation to actin organization, generating functional redundancy in the pathways that regulate actin cytoskeletal remodeling. [provided by RefSeq, Dec 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.